



## **Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024**

February 21, 2024

HAMILTON, Bermuda, Feb. 21, 2024 (GLOBE NEWSWIRE) -- [Kiniksa Pharmaceuticals, Ltd.](#) (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, February 28, 2024 at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2023 financial results and recent portfolio execution.

A live webcast will be accessible through the Investors & Media section of the company's website at [www.kiniksa.com](http://www.kiniksa.com). Individuals interested in participating in the call via telephone may register [here](#). Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa's website within approximately 48 hours after the event.

### **About Kiniksa**

Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's immune-modulating assets, ARCALYST<sup>®</sup>, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit [www.kiniksa.com](http://www.kiniksa.com).

ARCALYST<sup>®</sup> is a registered trademark of Regeneron Pharmaceuticals, Inc.

***Every Second Counts!***<sup>®</sup>

### **Kiniksa Investor and Media Contact**

Rachel Frank  
(339) 970-9437  
[rfrank@kiniksa.com](mailto:rfrank@kiniksa.com)